Last $0.71 USD
Change Today -0.0531 / -6.99%
Volume 1.5M
RNN On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

rexahn pharmaceuticals inc (RNN) Snapshot

Open
$0.75
Previous Close
$0.76
Day High
$0.78
Day Low
$0.71
52 Week High
01/13/14 - $1.85
52 Week Low
11/7/13 - $0.37
Market Cap
126.0M
Average Volume 10 Days
1.0M
EPS TTM
$-0.13
Shares Outstanding
178.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REXAHN PHARMACEUTICALS INC (RNN)

Related News

No related news articles were found.

rexahn pharmaceuticals inc (RNN) Related Businessweek News

No Related Businessweek News Found

rexahn pharmaceuticals inc (RNN) Details

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. The company is based in Rockville, Maryland.

16 Employees
Last Reported Date: 03/21/14

rexahn pharmaceuticals inc (RNN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $380.8K
President and Chief Operating Officer
Total Annual Compensation: $268.8K
Founder, Chairman of the Board and Chief Scie...
Total Annual Compensation: $319.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $270.1K
Compensation as of Fiscal Year 2013.

rexahn pharmaceuticals inc (RNN) Key Developments

Rexahn Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Rexahn Pharmaceuticals, Inc. reported financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations for the second quarter ended June 30, 2014 was $3.51 million, compared to a loss from operations of $1.91 million for the same quarter ended June 30, 2013. Net loss for the six months ended June 30, 2014 was $14.41 million, or $0.08 loss per share, compared to a net loss of $4.64 million, or $0.04 loss per share, for the same period ended June 30, 2013. Loss from operations for the six months ended June 30, 2014 was $6.27 million, compared to a loss from operations of $3.82 million for the same period ended June 30, 2013.

Rexahn Receives Notice of Allowance from the U.S. Patent and Trademark Office for Novel Targeted Cancer Drug Delivery Platform

Rexahn Pharmaceuticals, Inc. announced it has received a notice of allowance from the United States Patent and Trademark Office for a new delivery technology titled, Polymeric Systems for the Delivery of Anticancer Drugs. The patent covers CPMA, a new polymer drug delivery platform technology developed by Rexahn. The CPMA technology platform allows for multiple anti-cancer compounds to be covalently bound to the proprietary polymer backbone and be coupled to a signaling moiety. The signaling moiety directs the bound drug to the cancer cell, thereby bypassing healthy cells leading to enhanced efficacy with the potential for reduced side effects. Once inside the cancer cell the CPMA complex is metabolized yielding the free anticancer compound. Because of its diverse chemical properties, CPMA is highly water soluble which allows water insoluble anti-cancer compounds to be bioavailable through a more effective delivery.

Rexahn Pharmaceuticals, Inc. Reports Earnings Results for Second Quarter Ended June 30, 2014

Rexahn Pharmaceuticals reported earnings results for second quarter ended June 30, 2014. For the quarter the company reported net Income was $0.2 million, or $0.00 per share compared to a net loss of $14.6 million, or $0.09 per share, for the three months ended March 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RNN:US $0.71 USD -0.0531

RNN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RNN.
View Industry Companies
 

Industry Analysis

RNN

Industry Average

Valuation RNN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REXAHN PHARMACEUTICALS INC, please visit www.rexahn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.